In recent years, emerging diseases like COVID and Zika have shown how quickly viruses can spread and how hard it is to stay ahead. Air travel helps viruses move fast, and our treatments often can’t keep up. But scientists are working on new ways to respond faster, and one promising approach is making your own antibodies inside your body.

Why Broadly Neutralizing Antibodies Matter

When someone gets sick, their immune system produces antibodies to fight the virus. Some of these are weak, but others are called “broadly neutralizing antibodies,” which can attach to many variants of a virus or related viruses. These strong antibodies block the virus from infecting cells by binding to critical parts of the virus’s structure.

Unfortunately, not everyone makes these powerful antibodies naturally, and vaccines don’t always trigger their production. That’s why scientists have been trying to find ways to give people these antibodies directly. They can be made in labs and injected into patients, which has helped treat Ebola and even been used early in the COVID pandemic.

Limitations of Direct Antibody Injections

Injecting lab-made antibodies works but has drawbacks. The antibodies don’t last forever in the body, so people might need repeated shots. Also, producing enough for widespread use is expensive and complex. The antibodies need to be kept cold, which makes distribution tricky, especially in less-developed areas.

Because of these issues, researchers are exploring alternative methods that could let the body produce its own antibodies for longer periods. If successful, this could mean better protection that doesn’t rely on repeated injections.

Getting Your Cells to Make Antibodies

The key idea is to insert the genetic instructions for these antibodies into a person’s cells. Scientists can clone the genes that produce broadly neutralizing antibodies and put them into pieces of DNA called plasmids. When these plasmids enter cells, the cells can start making the antibodies on their own.

One approach uses harmless viruses to carry the DNA into cells, but this can cause unwanted immune reactions. So, researchers are trying a different method: using electrical pulses to open cell membranes temporarily. They mix the DNA with a solution and zap it with a small electric current, which helps the DNA get into muscle cells. These muscle cells then act as factories, producing lots of antibodies.

Early Human Trials Show Promise

A recent study tested this technique on 44 volunteers. They used different doses and injection schedules to see if it was safe. Most participants completed the trial, though some found the electric pulses uncomfortable. Side effects mainly included muscle soreness, skin redness, and small scabs at the injection site.

The results were encouraging. Most volunteers produced stable levels of the desired antibodies for at least 72 weeks. In some cases, more injections or higher doses increased antibody production, but even the smallest dose worked well. Importantly, these antibodies could block SARS-CoV-2, the virus that causes COVID.

Challenges and Future Outlook

While this method shows promise, it’s not ready for quick responses to new outbreaks. Identifying the right antibodies takes time, and the equipment needed for electric pulses isn’t common everywhere. Plus, producing long-lasting immunity could put pressure on the virus to evolve new variants that escape these antibodies.

Public acceptance might also be a hurdle. Some people are wary of gene-based treatments, especially after misconceptions about COVID vaccines. Explaining that the DNA in these treatments doesn’t permanently change your genes will be crucial.

In the end, this approach could be a game-changer if refined further. It offers a way to turn your body into a antibody-producing factory, potentially providing long-term protection against dangerous viruses. But more research is needed before it can be widely used in fighting future pandemics.

Inspired by

• https://arstechnica.com/science/2025/10/dna-and-jolts-of-electricity-get-people-to-make-optimal-antibodies/

Sources

• conde.digital
• cnevids.com
• doi.org